secwatch.observer — SEC 8-K summary
======================================

Issuer:     Inmune Bio, Inc. (INMB)
CIK:        0001711754
Form:       8-K
Filed at:   2024-04-26T23:59:59+00:00
Accession:  0001213900-24-036668
Event type: other_material
Sentiment:  neutral
Materiality: 0.70
Item codes: 1.01, 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

INmune Bio raises $9.7M in registered direct offering of common stock and warrants
--------------------------------------------------------------------------------

- Offering comprises 986,000 shares and warrants at $9.84 per unit; gross proceeds ~$9.7M.
- Warrants have acceleration clause upon positive Phase 2 Alzheimer's top-line data (XPro1595).
- Closing expected on or about April 29, 2024; Maxim Group LLC is sole placement agent.
- Net proceeds to fund Phase 2 Alzheimer's trial (AD02) and Phase 1 mCRPC trial (INKmune).
- Shares and warrants issued under effective shelf registration statement (S-3, No. 333-254221).

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1711754/000121390024036668/0001213900-24-036668-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1711754/000121390024036668/ea0204729-8k_inmune.htm
  HTML page:      https://secwatch.observer/filing/0001213900-24-036668

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer